Eli Lilly & Co. stock (US5324571083): Q1 revenues surge 56% on obesity drug boom

Eli Lilly & Co. posted Q1 2026 revenues of $19.8B, up 56% year-over-year, driven by Mounjaro and Zepbound sales. The stock retreated 2.72% to $948.45 amid profit-taking after a 13% post-earnings surge.

Eli Lilly & Co. released first-quarter 2026 results showing revenue of $19.8 billion, a 56% increase from the prior year, fueled by blockbuster sales of obesity treatment Mounjaro at $8.66 billion (+125% YoY) and diabetes drug Zepbound at $4.16 billion (+80% YoY), Pluang as of May 2026. Earnings per share hit $8.55, beating consensus estimates of $6.66, sparking a 13% stock rally last week before recent pullback. The pharmaceutical giant maintained its strong buy rating amid robust demand for GLP-1 therapies.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Eli Lilly & Co.
• Sector/industry: Healthcare / Drug Manufacturers – General
• Headquarters/country: USA
• Core markets: United States, Europe, China, Japan
• Key revenue drivers: Obesity and diabetes drugs like Mounjaro, Zepbound
• Home exchange/listing venue: NYSE (LLY)
• Trading currency: USD

Eli Lilly & Co.: core business model

Eli Lilly & Co. discovers, develops, manufactures and markets human pharmaceutical products worldwide, with a focus on neuroscience, cardiometabolic health, cancer and immunology, The Bull as of May 2026. The company generates scale through diversified portfolios, reporting trailing twelve-month revenue of $65.2 billion and a market cap around $790 billion. Its business model emphasizes innovation in high-growth areas like GLP-1 receptor agonists for weight management and diabetes.

Key to its operations is a robust R&D pipeline, supported by global manufacturing. Lilly serves major markets including the US, where it holds significant share in endocrinology therapies relevant to American investors tracking healthcare spending trends.

Main revenue and product drivers for Eli Lilly & Co.

Mounjaro and Zepbound dominate recent growth, with Q1 2026 sales reflecting surging US demand for obesity treatments amid rising prevalence rates. Overall revenue growth hit 55.5% in latest figures, with profit margins at 34.99%, per The Bull as of May 2026. Other contributors include established drugs in oncology and immunology, providing revenue stability.

The stock traded at $948.45 USD on recent sessions on NYSE, down 2.72% from prior levels, following a post-earnings surge, according to Pluang as of May 2026. Dividend yield stands at 0.65%, with next payout of $1.73 per share planned.

Industry trends and competitive position

Eli Lilly & Co. leads the GLP-1 market alongside rivals, benefiting from US payer coverage expansions for obesity drugs. Q1 results underscore its edge in manufacturing scale, with return on equity at 105.77% for the period ending Q1 2026, MarketBeat as of 05/11/2026. Partnerships like with Omada Health expand direct-to-employer channels.

Why Eli Lilly & Co. matters for US investors

As a NYSE-listed leader in US healthcare innovation, Eli Lilly & Co. offers exposure to the $100B+ obesity market projected through decade-end. Its drugs address epidemic-level needs, with strong US revenue weighting making it a key holding for portfolios focused on American demographic shifts and biotech growth.

Conclusion

Eli Lilly & Co. delivered standout Q1 2026 performance with 56% revenue growth led by obesity and diabetes franchises. While shares pulled back after initial gains, fundamentals reflect sustained momentum in high-demand therapies. Investors monitor pipeline progress and market dynamics in this competitive sector.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.